aTyr Pharma (NASDAQ: LIFE) reported Q2 EPS of $0.53. Revenue for the quarter came in at $189.56 million.

GUIDANCE:

aTyr Pharma sees Q3 2026 revenue of $160-164 million, versus the consensus of $120 million.

aTyr Pharma sees FY2026 revenue of $727-731 million, versus the consensus of $568.4 million.

For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.